Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157334/
https://www.ncbi.nlm.nih.gov/pubmed/35640932
http://dx.doi.org/10.1136/jitc-2022-004699corr1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157334/
https://www.ncbi.nlm.nih.gov/pubmed/35640932
http://dx.doi.org/10.1136/jitc-2022-004699corr1

Ejemplares similares